Strides Pharma Science Ltd

Strides Pharma Science announced that Puneet Kumar Malik, Senior Management Personnel of the Company has desired to relinquish his position w.e.f. close of business hours on 31 January 2026 to pursue other opportunity within the Aditya Birla Group.Powered by Capital Market - Live

Strides Pharma Science announced that Surabhi Loshali, Group CHRO of the Company, has resigned from Strides to pursue her personal and professional aspirations. Her last working day with Strides shall be closing business hours of 02 January 2026.Powered by Capital Market - Live

Net profit of Strides Pharma Science rose 77.52% to Rs 127.53 crore in the quarter ended September 2025 as against Rs 71.84 crore during the previous quarter ended September 2024. Sales rose 4.62% to Rs 1220.83 crore in the quarter ended September 2025 as against Rs 1166.93 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales1220.831166.93 5 OPM %18.8815.76 - PBDT211.53138.53 53 PBT161.8990.08 80 NP127.5371.84 78 Powered by Capital Market - Live

Profit before tax (PBT) climbed 77.62% YoY to Rs 153.11 crore in Q2 FY26. EBITDA stood at Rs 231.6 crore in Q2 FY26, registering the growth of 25.4% compared with Rs 184.6 crore in Q2 FY25. EBITDA margin improved by 320 bps to 19% in Q2 FY26 as against 15.8% in Q2 FY25. Revenue from the US market rose 2% year-on-year to $73 million in Q2 FY26, while revenue from other regulated markets increased 16% YoY to $44 million during the quarter. Badree Komandur, MD & Group CEO, said, 'Strides continues to deliver a strong performance in Q2FY26, with growth primarily driven by the other regulated markets. Our focus on profitability enabled the gross margin growth of 15% YoY, and EBITDA growth of 25% YoY. Operational PAT stood at Rs 140.3 crore, up 84% YoY, with EPS rising to Rs 15.2 for the quarter. Net debt reduced sequentially by Rs 46.9 crore despite currency headwinds and ongoing capex investments, reaffirming our strong financial discipline and focus on balance sheet health. This performance demonstrates our consistent execution as we continue to invest in sustainable, long-term growth.' Strides Pharma Science is global pharmaceutical company headquartered in Bangalore, India. It develops and manufactures wide range of niche and technically complex pharmaceutical products.Powered by Capital Market - Live

Strides Pharma Science will hold a meeting of the Board of Directors of the Company on 31 October 2025.Powered by Capital Market - Live

Under the terms of the agreement, Strides will collaborate with Kenox on the development and regulatory filing of multiple nasal spray products for the US market, spanning various therapeutic indications. The partnership aims to leverage Kenox's specialized expertise in OINDPs and Strides' strong presence in regulated markets. 'We are delighted to announce this partnership with Kenox, a company that brings deep technical expertise in the OINDP space,' said Aditya Kumar, executive director ' business development, Strides Pharma Science. 'Nasal sprays have consistently been a key focus area for Strides, and this collaboration builds on the solid progress we've already made in this domain. With our continued investments in capabilities and capacities at our US facility, these products are a natural extension of our strategy to grow in the nasal spray technology segment. Kenox's formulation and development strengths perfectly complement our manufacturing and go-to-market capabilities, enabling us to accelerate the expansion of our nasal spray portfolio in the US market.' Dr. Sitaram Velaga, founder, president, and CEO of Kenox Pharmaceuticals Inc., added, 'Our strategic partnership with Strides marks a significant milestone for Kenox. This collaboration validates our expertise in the OINDP space and enables us to leverage our capabilities to bring important drug products to patients worldwide at an affordable price.' The partnership aims to advance a pipeline of nasal spray products for the US market, combining Strides' strong commercial presence with Kenox's specialized OINDP expertise to deliver high-quality, affordable therapies to patients. The company's consolidated net profit plunged 96.8% to Rs 105.59 crore in Q1 FY26, compared to Rs 3,349.58 crore reported in Q1 FY25. Meanwhile, net sales increased 6.2% year-on-year to Rs 1,119.47 crore during the quarter. Shares of Strides Pharma Science rose 0.07% to Rs 881.70 on the BSE. Powered by Capital Market - Live

Net profit of Strides Pharma Science declined 97.03% to Rs 99.61 crore in the quarter ended June 2025 as against Rs 3351.47 crore during the previous quarter ended June 2024. Sales rose 6.20% to Rs 1119.74 crore in the quarter ended June 2025 as against Rs 1054.34 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales1119.741054.34 6 OPM %19.4817.87 - PBDT179.30128.64 39 PBT130.4182.12 59 NP99.613351.47 -97 Powered by Capital Market - Live

Strides Pharma Science will hold a meeting of the Board of Directors of the Company on 29 July 2025.Powered by Capital Market - Live

Strides Pharma Science announced that the 34th Annual General Meeting(AGM) of the company will be held on 7 August 2025.Powered by Capital Market - Live

Strides Pharma Science has fixed 22 July 2025 as record date for final dividend of Rs 4 per share of face value of Rs 10 each for FY 2025. Powered by Capital Market - Live